100% Quality Guarantee
PhD-Level Technical Support
Human IL1B/IL1F2 (CDP484) Antibody - SDS-PAGE
Key Features

Human IL1B/IL1F2 (CDP484) Antibody (GXBS01626)

SKU GXBS01626
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Human
Reactivity Human
Applications ELISA, FACS, Functional assay, Research in vivo
Clone ID CDP484
Isotype IgG
$677 - $2,208

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human IL1B/IL1F2 (CDP484) Antibody

Human IL1B/IL1F2 (CDP484) Antibody is a research-grade biosimilar monoclonal antibody targeting Interleukin-1 beta. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Interleukin-1 beta (IL1B/IL1F2) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6. IL1B is the therapeutic target of canakinumab (Ilaris).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose